Stockscreener 앱 받기
1.91
2.14%
0.04
시장 영업 전:
1.91
전일 마감가:
$1.87
열려 있는:
$1.835
하루 거래량:
3.82M
Relative Volume:
4.13
시가총액:
$252.18M
수익:
$79,600
순이익/손실:
$-48.26M
주가수익비율:
-3.8805
EPS:
-0.4922
순현금흐름:
$-28.24M
1주 성능:
+4.37%
1개월 성능:
+12.35%
6개월 성능:
-4.50%
1년 성능:
+15.76%
1일 변동 폭
$1.835
$1.93
1주일 범위
$1.785
$1.93
52주 변동 폭
$1.33
$2.26
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.91 | 252.18M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-04 | 개시 | Ladenburg Thalmann | Buy |
| 2026-01-21 | 개시 | BofA Securities | Buy |
| 2025-12-26 | 개시 | H.C. Wainwright | Buy |
| 2025-12-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Inhibikase (NASDAQ: IKT) investors back 3M-share plan boost and officer protections - Stock Titan
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to sales forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to sales forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Price to earnings forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Price to book forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Inhibikase Therapeutics, Inc. Actuals & Estimates (NASDAQ:IKT) - TradingView
IKT Forecast — Price Target — Prediction for 2027 - TradingView
Inhibikase Therapeutics Inc (IKT) Institutional Confidence - TradingKey
Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Inhibikase Therapeutics Inc (IKT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Inhibikase Therapeutics Inc (IKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Inhibikase Therapeutics Inc (IKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Inhibikase Therapeutics Inc (IKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibikase Therapeutics (IKT) Consolidates Near $1.67 – Key Levels in FocusTriple Bottom - newsline.com
IKT Initiates Coverage On Oppenheimer -- Rating Set to Outperfor - GuruFocus
Oppenheimer Initiates Inhibikase Therapeutics at Outperform - marketscreener.com
Inhibikase Therapeutics (IKT) Tests Support Zone After Slight DeclineFibonacci Entry Signals - newsline.com
IKT Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesEarnings Recovery Stocks - newsline.com
Inhibikase Therapeutics (IKT) Edges Higher, Testing Key Resistance Amid Biotech Sector UncertaintyCTA Positioning - newsline.com
Inhibikase Therapeutics (IKT) Narrows Lower: Testing Key Support Near $1.61Size Factor - newsline.com
IKT Q1 2026 Earnings: Narrow EPS Beat as Clinical Pipeline Progress ContinuesQuarterly Financial Update - newsline.com
Inhibikase Therapeutics (IKT) Holds Near Support Amid Biotech Sector HeadwindsLiquidity Order Flow - newsline.com
Inhibikase Therapeutics (IKT) Recovers 3.5% as Buyers Defend Key Support LevelMAMA Signal - The Legal Advocate
Inhibikase Therapeutics (IKT) Holds Near Support Amid Narrow Trading RangeScalping Stock Signals - The Legal Advocate
H.C. Wainwright Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Pulmonary Arterial Hypertension Market Outlook Shows Strong Upward Trend at a CAGR of 6.7% During the Study Period (2022-2036) Supported by New Clinical Developments | DelveInsight - Fidelity
Inhibikase Therapeutics (IKT) Faces Selling Pressure as Stock Retreats to $1.69Parabolic SAR - Newser
Inhibikase Therapeutics (IKT) Q1 2026 Earnings: Narrowing Losses as Pipeline Progress Takes Center StageShared Momentum Picks - Newser
IKT SEC FilingsInhibikase Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Inhibikase Gains EU Clearance for Global PAH Trial - MyChesCo
Inhibikase Therapeutics, Inc. (IKT) Competitors - Meyka
IKT Stock Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 By Investing.com - Investing.com Nigeria
Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Cantor Fitzgerald Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Cantor Fitzgerald reiterates Inhibikase stock Overweight rating at $4 - Investing.com India
Bank of America Securities Reaffirms Their Buy Rating on Inhibikase Therapeutics (IKT) - The Globe and Mail
BofA Securities Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $6 - Moomoo
ADAR1 reports 9.9% stake in Inhibikase (NASDAQ: IKT) via managed accounts - Stock Titan
Trails Edge holds 8.06M Inhibikase shares — Trails Edge (NASDAQ: IKT) - Stock Titan
Commodore Capital (IKT) reports 14.05M shares equivalent, 9.9% cap - Stock Titan
Perceptive Advisors/Perceptive Life Sciences disclose 8.9% holding in IKT (IKT) - Stock Titan
Maxim Group Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.36%
자본화:
|
볼륨(24시간):